In 2022, the incidence of lung cancer among men in Europe was highest in Hungary at ***** per 100,000, while Sweden had the lowest incidence. The incidence of lung cancer recorded among women in Denmark was over ** per 100,000 population. Across the European Union overall, the rate of lung cancer diagnoses was **** per 100,000 among men and **** per 100,000 among women. Smoking and lung cancer risk The connection between smoking and the increased risk of health problems is well established. As of 2021, Hungary had one of the highest daily smoking rates in Europe, with over a quarter of adults smoking daily in the Central European country. The only other countries with a higher share of smoking adults were Bulgaria and Turkey. A positive development though, is the share of adults smoking every day has decreased in almost every European country since 2011. The rise of vaping Originally marketed as a device to help smokers quit, e-cigarettes or vapes have seen increased popularity among people who never smoked cigarettes, especially young people. The use of vapes among young people was reported to be highest in Estonia, Czechia, and Ireland. The dangers of vaping have not been examined over the long term. In the EU there have been attempts to make ‘vapes’ less accessible and appealing for young people, which would include such things as banning flavors and stopping the sale of disposable e-cigarettes.

As of 2022, the age-standardized incidence rate of lung cancer worldwide was 23.6 per 100,000 population. At this time, the incidence rate of lung cancer was highest in Eastern Asia. This statistic shows the age-standardized incidence rate of lung cancer worldwide as of 2022, by region.

This dataset contains data about lung cancer Mortality. This database is a comprehensive collection of patient information, specifically focused on individuals diagnosed with cancer. It is designed to facilitate the analysis of various factors that may influence cancer prognosis and treatment outcomes. The database includes a range of demographic, medical, and treatment-related variables, capturing essential details about each patient's condition and history.

Key components of the database include:

Demographic Information: Basic details about the patients such as age, gender, and country of residence. This helps in understanding the distribution of cancer cases across different populations and regions.

Medical History: Information about each patient’s medical background, including family history of cancer, smoking status, Body Mass Index (BMI), cholesterol levels, and the presence of other health conditions such as hypertension, asthma, cirrhosis, and other cancers. This section is crucial for identifying potential risk factors and comorbidities.

Cancer Diagnosis: Detailed data about the cancer diagnosis itself, including the date of diagnosis and the stage of cancer at the time of diagnosis. This helps in tracking the progression and severity of the disease.

Treatment Details: Information regarding the type of treatment each patient received, the end date of the treatment, and the outcome (whether the patient survived or not). This is essential for evaluating the effectiveness of different treatment approaches.

The structure of the database allows for in-depth analysis and research, making it possible to identify patterns, correlations, and potential causal relationships between various factors and cancer outcomes. It is a valuable resource for medical researchers, epidemiologists, and healthcare providers aiming to improve cancer treatment and patient care.

id: A unique identifier for each patient in the dataset. age: The age of the patient at the time of diagnosis. gender: The gender of the patient (e.g., male, female). country: The country or region where the patient resides. diagnosis_date: The date on which the patient was diagnosed with lung cancer. cancer_stage: The stage of lung cancer at the time of diagnosis (e.g., Stage I, Stage II, Stage III, Stage IV). family_history: Indicates whether there is a family history of cancer (e.g., yes, no). smoking_status: The smoking status of the patient (e.g., current smoker, former smoker, never smoked, passive smoker). bmi: The Body Mass Index of the patient at the time of diagnosis. cholesterol_level: The cholesterol level of the patient (value). hypertension: Indicates whether the patient has hypertension (high blood pressure) (e.g., yes, no). asthma: Indicates whether the patient has asthma (e.g., yes, no). cirrhosis: Indicates whether the patient has cirrhosis of the liver (e.g., yes, no). other_cancer: Indicates whether the patient has had any other type of cancer in addition to the primary diagnosis (e.g., yes, no). treatment_type: The type of treatment the patient received (e.g., surgery, chemotherapy, radiation, combined). end_treatment_date: The date on which the patient completed their cancer treatment or died. survived: Indicates whether the patient survived (e.g., yes, no).

This dataset contains artificially generated data with as close a representation of reality as possible. This data is free to use without any licence required.

Good luck Gakusei!

In 2022, the mortality rate of lung cancer in the European was **** per 100,000 men and **** per 100,000 women. Among men the mortality rate was highest in Hungary and lowest in Sweden being *** and **** per 100,000 respectively. Hungary was also the country with the highest lung cancer mortality rate in women with **** per 100,000 women. The lowest was in Lithuania with **** per 100,000 women. In most EU countries, there was a marked difference between the mortality of lung cancer in men and women.

This dataset provides valuable insights into lung cancer cases, risk factors, smoking trends, and healthcare access across 25 of the world's most populated countries. It includes 220,632 individuals with details on their age, gender, smoking history, cancer diagnosis, environmental exposure, and survival rates. The dataset is useful for medical research, predictive modeling, and policy-making to understand lung cancer patterns globally.

In 2022, the highest cancer rate for men and women among European countries was in Denmark with 728.5 cancer cases per 100,000 population. Ireland and the Netherlands followed, with 641.6 and 641.4 people diagnosed with cancer per 100,000 population, respectively.
Lung cancer Lung cancer is the deadliest type of cancer worldwide, and in Europe, Germany was the country with the highest number of lung cancer deaths in 2022, with 47.7 thousand deaths. However, when looking at the incidence rate of lung cancer, Hungary had the highest for both males and females, with 138.4 and 72.3 cases per 100,000 population, respectively.
Breast cancer Breast cancer is the most common type of cancer among women with an incidence rate of 83.3 cases per 100,000 population in Europe in 2022. Cyprus was the country with the highest incidence of breast cancer, followed by Belgium and France. The mortality rate due to breast cancer was 34.8 deaths per 100,000 population across Europe, and Cyprus was again the country with the highest figure.

This dataset helps understand and predict lung cancer risks based on health, environment, and lifestyle factors. It includes details about smoking habits, pollution exposure, healthcare access, and survival chances.

Doctors, researchers, and data scientists can use it to find patterns in lung cancer cases and improve early detection.

Columns Breakdown (25 Features) Country – The country where the patient resides Age – Patient’s age (randomized between 30-90) Gender – Male/Female Smoking_Status – Smoker, Non-Smoker, Former Smoker Second_Hand_Smoke – Yes/No Air_Pollution_Exposure – Low, Medium, High Occupation_Exposure – Yes/No (Factory, Mining, etc.) Rural_or_Urban – Rural/Urban Socioeconomic_Status – Low, Middle, High Healthcare_Access – Good, Limited, Poor Insurance_Coverage – Yes/No Screening_Availability – Yes/No Stage_at_Diagnosis – I, II, III, IV Cancer_Type – NSCLC, SCLC Mutation_Type – EGFR, ALK, KRAS, None Treatment_Access – Full, Partial, None Clinical_Trial_Access – Yes/No Language_Barrier – Yes/No Mortality_Risk – Probability (0.0 - 1.0) 5_Year_Survival_Probability – Probability (0.0 - 1.0) Delay_in_Diagnosis – Yes/No Family_History – Yes/No Indoor_Smoke_Exposure – Yes/No Tobacco_Marketing_Exposure – Yes/No Final_Prediction – Lung Cancer (Yes/No)

In 2018, Hungary reported ***** new lung cancer cases per 100,000 population, the highest incidence of lung cancer in Europe in that year. This was followed by an incidence rate of **** lung cancer cases in Greece. In comparison, **** cases of lung cancer per 100,000 were diagnosed in Sweden

BackgroundLung cancer is a significant health concern in China. There is limited available data of its burden and trends. This study aims to evaluate the trends of lung cancer across different age groups and genders in China and the Group of Twenty (G20) countries, explore the risk factors, and predict the future trends over a 20-year period.MethodsThe data were obtained from the GBD study 2019. The number of cases, age standardized rate (ASR), and average annual percentage changes (AAPC) were used to estimate the trend in lung cancer by age, gender, region and risk factor. The trend of lung cancer was predicted by autoregressive integrated moving average (ARIMA) model by the “xtarimau” command. The joinpoint regression analysis was conducted to identify periods with the highest changes in incidence and mortality. Additionally, the relationship between AAPCs and socio-demographic index (SDI) was explored.ResultsFrom 1990 to 2019, both the incidence and mortality of lung cancer in China and G20 significantly increased, with China experiencing a higher rate of increase. The years with the highest increase in incidence of lung cancer in China were 1998-2004 and 2007-2010. Among the G20 countries, the AAPC in incidence and mortality of lung cancer in the Republic of Korea was the highest, followed closely by China. Although India exhibited similarities, its AAPC in lung cancer incidence and mortality rates was lower than that of China. The prediction showed that the incidence in China will continue to increase. In terms of risk factors, smoking was the leading attributable cause of mortality in all countries, followed by occupational risk and ambient particulate matter pollution. Notably, smoking in China exhibited the largest increase among the G20 countries, with ambient particulate matter pollution ranking second.ConclusionLung cancer is a serious public health concern in China, with smoking and environmental particulate pollution identified as the most important risk factors. The incidence and mortality rates are expected to continue to increase, which places higher demands on China’s lung cancer prevention and control strategies. It is urgent to tailor intervention measures targeting smoking and environmental pollution to contain the burden of lung cancer.

Lung Cancer Diagnostic Tests Market Outlook

The lung cancer diagnostic tests market size was valued at USD 2.5 billion in 2023 and is projected to reach USD 6.1 billion by 2032, growing at a Compound Annual Growth Rate (CAGR) of 10.5% during the forecast period. This substantial growth can be attributed to the rising prevalence of lung cancer globally, advancements in diagnostic technologies, and increasing awareness regarding early detection and treatment of lung cancer. The growing aging population and the high incidence of smoking, which is a leading cause of lung cancer, further propel the demand for diagnostic tests.

The increasing prevalence of lung cancer is one of the primary drivers of market growth. Lung cancer remains the leading cause of cancer-related deaths worldwide, necessitating the development of more accurate and early diagnostic methods. With advancements in medical technology, such as molecular diagnostics and non-invasive imaging techniques, the accuracy and efficiency of lung cancer diagnosis have significantly improved. These innovations not only enhance the detection rate but also facilitate personalized treatment plans, thereby improving patient outcomes.

Furthermore, government initiatives and funding for cancer research play a crucial role in market expansion. Many countries are investing heavily in cancer research, leading to the development of new diagnostic tools and techniques. For instance, organizations such as the National Cancer Institute (NCI) in the United States provide substantial grants for lung cancer research, fostering innovations in diagnostics. In addition, public awareness campaigns and screening programs conducted by healthcare organizations and governments encourage early diagnosis, which is vital for successful treatment and survival rates.

The integration of artificial intelligence (AI) and machine learning in diagnostic tools is another significant factor contributing to market growth. AI algorithms can analyze medical images with high precision, aiding radiologists in identifying lung cancer at earlier stages. Moreover, AI-driven software can evaluate large datasets from genetic and molecular tests, providing insights into the most effective treatment options based on individual patient profiles. This technological advancement not only enhances the accuracy of diagnostics but also reduces the time required for analysis, thereby increasing the efficiency of healthcare services.

The EGFR Mutation Test is a pivotal advancement in the realm of lung cancer diagnostics, offering a more personalized approach to treatment. This test specifically identifies mutations in the Epidermal Growth Factor Receptor (EGFR) gene, which are often present in non-small cell lung cancer (NSCLC) patients. By detecting these mutations, healthcare providers can tailor therapies that target the specific genetic alterations, thereby improving treatment efficacy and patient outcomes. The growing adoption of EGFR Mutation Tests underscores the shift towards precision medicine, where treatments are increasingly customized based on individual genetic profiles. This approach not only enhances the effectiveness of therapies but also minimizes adverse effects, as treatments are more accurately aligned with the patient's unique genetic makeup.

Regionally, North America holds the largest share of the lung cancer diagnostic tests market, followed by Europe and Asia Pacific. The dominance of North America can be attributed to the presence of advanced healthcare infrastructure, high healthcare expenditure, and a robust research landscape. The Asia Pacific region, however, is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, growing awareness about lung cancer, and rising incidences of the disease in countries like China and India. The growing middle-class population and improving healthcare access in these countries further support market growth.

Test Type Analysis

The lung cancer diagnostic tests market is segmented by test type into imaging tests, sputum cytology, tissue biopsy, molecular tests, and others. Imaging tests are one of the most commonly used diagnostic methods for lung cancer detection. Techniques such as X-rays, CT scans, and PET scans provide detailed visuals of the lungs, helping in identifying abnormal growths or tumors. The non-invasive nature of these tests and their ability to provide quick results make them a preferred choice among healthcare

BackgroundBetter information on lung cancer occurrence in lifelong nonsmokers is needed to understand gender and racial disparities and to examine how factors other than active smoking influence risk in different time periods and geographic regions. Methods and FindingsWe pooled information on lung cancer incidence and/or death rates among self-reported never-smokers from 13 large cohort studies, representing over 630,000 and 1.8 million persons for incidence and mortality, respectively. We also abstracted population-based data for women from 22 cancer registries and ten countries in time periods and geographic regions where few women smoked. Our main findings were: (1) Men had higher death rates from lung cancer than women in all age and racial groups studied; (2) male and female incidence rates were similar when standardized across all ages 40+ y, albeit with some variation by age; (3) African Americans and Asians living in Korea and Japan (but not in the US) had higher death rates from lung cancer than individuals of European descent; (4) no temporal trends were seen when comparing incidence and death rates among US women age 40–69 y during the 1930s to contemporary populations where few women smoke, or in temporal comparisons of never-smokers in two large American Cancer Society cohorts from 1959 to 2004; and (5) lung cancer incidence rates were higher and more variable among women in East Asia than in other geographic areas with low female smoking. ConclusionsThese comprehensive analyses support claims that the death rate from lung cancer among never-smokers is higher in men than in women, and in African Americans and Asians residing in Asia than in individuals of European descent, but contradict assertions that risk is increasing or that women have a higher incidence rate than men. Further research is needed on the high and variable lung cancer rates among women in Pacific Rim countries.

Lung Cancer Diagnostics Market Outlook

According to our latest research, the global lung cancer diagnostics market size in 2024 is valued at USD 3.2 billion, with a robust compound annual growth rate (CAGR) of 7.8% projected from 2025 to 2033. By the end of 2033, the market is forecasted to reach USD 6.3 billion, reflecting sustained demand for advanced diagnostic solutions. This growth is primarily driven by the rising incidence of lung cancer worldwide, increased adoption of early detection technologies, and ongoing advancements in molecular and imaging diagnostics that enhance both accuracy and speed of detection.

A major growth factor for the lung cancer diagnostics market is the alarming rise in lung cancer prevalence, which remains one of the leading causes of cancer-related deaths globally. The World Health Organization reports that lung cancer accounts for more than 2.2 million new cases and nearly 1.8 million deaths annually. This high disease burden has prompted governments and healthcare organizations to prioritize early detection and screening programs. Additionally, the growing awareness among patients and healthcare providers about the benefits of early diagnosis has led to increased screening rates, further fueling market expansion. The development of non-invasive and minimally invasive diagnostic techniques, such as liquid biopsies and advanced imaging modalities, has also played a pivotal role in enhancing patient compliance and improving diagnostic accuracy.

Technological innovation is another significant driver propelling the lung cancer diagnostics market forward. The integration of next-generation sequencing (NGS), polymerase chain reaction (PCR), and immunohistochemistry (IHC) technologies into routine clinical practice has revolutionized the detection and characterization of lung tumors. These technologies facilitate the identification of genetic mutations and biomarkers associated with lung cancer, enabling personalized treatment approaches and improving patient outcomes. Furthermore, the emergence of artificial intelligence (AI) and machine learning algorithms is improving the interpretation of diagnostic images and pathology slides, reducing human error and shortening turnaround times. As healthcare systems increasingly embrace digital transformation, these innovations are expected to further accelerate market growth.

The expanding geriatric population and rising tobacco consumption, particularly in developing regions, are additional factors contributing to the growth of the lung cancer diagnostics market. Older adults are at a higher risk for lung cancer, and the aging global population is expected to drive demand for effective diagnostic solutions. Simultaneously, the high prevalence of smoking in countries such as China, India, and Russia continues to elevate lung cancer incidence rates. These demographic and lifestyle trends, combined with improved access to healthcare infrastructure and government initiatives to subsidize cancer screening, are expected to sustain market momentum over the forecast period.

Breast Cancer Diagnostics have seen significant advancements, paralleling the developments in lung cancer diagnostics. The integration of molecular and imaging technologies has improved the accuracy and speed of breast cancer detection, much like in lung cancer. Innovations such as digital mammography, MRI, and ultrasound are enhancing early detection capabilities, leading to better patient outcomes. The adoption of personalized medicine approaches, driven by genetic and biomarker testing, is also transforming breast cancer diagnostics. As with lung cancer, the emphasis on early detection and tailored treatment plans is crucial in managing breast cancer effectively. The continuous evolution of diagnostic tools and techniques is expected to further improve the landscape of breast cancer diagnostics, aligning with the broader trends observed in oncology diagnostics.

From a regional perspective, North America currently dominates the lung cancer diagnostics market, accounting for the largest share in 2024, followed by Europe and Asia Pacific. The United States, in particular, benefits from advanced healthcare infrastructure, significant investments in cancer research, and widespread adoption of innovative diagn

This dataset contains information on lung cancer risk factors across various countries, focusing on demographic details, smoking behaviors, and family history. Researchers and public health professionals can use this data to study patterns of lung cancer incidence, identify trends related to smoking and passive smoking exposure, and assess the impact of family history on lung cancer risk.

What You Can Perform with This Data:

Risk Factor Analysis: Analyze how smoking habits, exposure to secondhand smoke, and family history correlate with lung cancer risk. Comparative Study: Compare lung cancer risk factors across different countries and regions. Demographic Insights: Explore how age and gender impact the prevalence of lung cancer risk factors. Statistical Modeling: Build models to predict lung cancer risk based on various factors such as smoking history, exposure to passive smoke, and genetic predisposition. Public Health Research: Identify populations with high-risk behaviors and suggest interventions or preventive measures.

As of 2022, the age-standardized incidence rate of lung cancer among males in Polynesia was 54.7 per 100,000 population, the highest rate worldwide. The incidence rate of lung cancer among females was highest in Northern America. This statistic shows the age-standardized incidence rate of lung cancer worldwide as of 2022, by region and gender.

Dataset Description This dataset contains information on cancer deaths by country, type, and year. It includes data on 18 different types of cancer, including liver cancer, kidney cancer, larynx cancer, breast cancer, thyroid cancer, stomach cancer, bladder cancer, uterine cancer, ovarian cancer, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, testicular cancer, nasopharynx cancer, other pharynx cancer, colon and rectum cancer, non-melanoma skin cancer, lip and oral cavity cancer, brain and nervous system cancer, tracheal, bronchus, and lung cancer, gallbladder and biliary tract cancer, malignant skin melanoma, leukemia, Hodgkin lymphoma, multiple myeloma, and other cancers.

Data Fields The dataset includes the following data fields:

• Country: The country where the cancer death occurred.
• Code: The country code for the country where the cancer death occurred.
• Year: The year in which the cancer death occurred.
• Liver cancer: The number of cancer deaths from liver cancer in the country in the year.
• Kidney cancer: The number of cancer deaths from kidney cancer in the country in the year.
• Larynx cancer: The number of cancer deaths from larynx cancer in the country in the year.
• Breast cancer: The number of cancer deaths from breast cancer in the country in the year.
• Thyroid cancer: The number of cancer deaths from thyroid cancer in the country in the year.
• Stomach cancer: The number of cancer deaths from stomach cancer in the country in the year.
• Bladder cancer: The number of cancer deaths from bladder cancer in the country in the year.
• Uterine cancer: The number of cancer deaths from uterine cancer in the country in the year.
• Ovarian cancer: The number of cancer deaths from ovarian cancer in the country in the year.
• Cervical cancer: The number of cancer deaths from cervical cancer in the country in the year.
• Prostate cancer: The number of cancer deaths from prostate cancer in the country in the year.
• Pancreatic cancer: The number of cancer deaths from pancreatic cancer in the country in the year.
• Esophageal cancer: The number of cancer deaths from esophageal cancer in the country in the year.
• Testicular cancer: The number of cancer deaths from testicular cancer in the country in the year.
• Nasopharynx cancer: The number of cancer deaths from nasopharynx cancer in the country in the year.
• Other pharynx cancer: The number of cancer deaths from other pharynx cancer in the country in the year.
• Colon and rectum cancer: The number of cancer deaths from colon and rectum cancer in the country in the year.
• Non-melanoma skin cancer: The number of cancer deaths from non-melanoma skin cancer in the country in the year.
• Lip and oral cavity cancer: The number of cancer deaths from lip and oral cavity cancer in the country in the year.
• Brain and nervous system cancer: The number of cancer deaths from brain and nervous system cancer in the country in the year.
• Tracheal, bronchus, and lung cancer: The number of cancer deaths from tracheal, bronchus, and lung cancer in the country in the year.
• Gallbladder and biliary tract cancer: The number of cancer deaths from gallbladder and biliary tract cancer in the country in the year.
• Malignant skin melanoma: The number of cancer deaths from malignant skin melanoma in the country in the year.
• Leukemia: The number of cancer deaths from leukemia in the country in the year.
• Hodgkin lymphoma: The number of cancer deaths from Hodgkin lymphoma in the country in the year.
• Multiple myeloma: The number of cancer deaths from multiple myeloma in the country in the year.
• Other cancers: The number of cancer deaths from other cancers in the country in the year.

Data Source The data in this dataset was collected from the World Health Organization (WHO). The WHO collects data on cancer deaths from countries around the world.

Usage This dataset can be used to study cancer deaths by country, type, and year. It can also be used to compare cancer death rates between different countries or over time.

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16169071%2F98f6c6f321aad496b703685519b6df6a%2Fcancer-cells-th.jpg?generation=1694610742970317&alt=media" alt="">

BackgroundUnderstanding the effects of demographic drivers on lung cancer mortality trends is critical for lung cancer control. We have examined the drivers of lung cancer mortality at the global, regional, and national levels.MethodsData on lung cancer death and mortality were extracted from the Global Burden of Disease (GBD) 2019. Estimated annual percentage change (EAPC) in the age-standardized mortality rate (ASMR) for lung cancer and all-cause mortality were calculated to measure temporal trends in lung cancer from 1990 to 2019. Decomposition analysis was used to analyze the contributions of epidemiological and demographic drivers to lung cancer mortality.ResultsDespite a non-significant decrease in ASMR [EAPC = −0.31, 95% confidence interval (CI): −1.1 to 0.49], the number of deaths from lung cancer increased by 91.8% [95% uncertainty interval (UI): 74.5–109.0%] between 1990 and 2019. This increase was due to the changes in the number of deaths attributable to population aging (59.6%), population growth (56.7%), and non-GBD risks (3.49%) compared with 1990 data. Conversely, the number of lung cancer deaths due to GBD risks decreased by 19.8%, mainly due to tobacco (−12.66%), occupational risks (−3.52%), and air pollution (−3.47%). More lung cancer deaths (1.83%) were observed in most regions, which were due to high fasting plasma glucose levels. The temporal trend of lung cancer ASMR and the patterns of demographic drivers varied by region and gender. Significant associations were observed between the contributions of population growth, GBD risks and non-GBD risks (negative), population aging (positive), and ASMR in 1990, the sociodemographic index (SDI), and the human development index (HDI) in 2019.ConclusionPopulation aging and population growth increased global lung cancer deaths from 1990 to 2019, despite a decrease in age-specific lung cancer death rates due to GBD risks in most regions. A tailored strategy is needed to reduce the increasing burden of lung cancer due to outpacing demographic drivers of epidemiological change globally and in most regions, taking into account region- or gender-specific risk patterns.

This dataset provides estimates for deaths, disability-adjusted life years (DALYs), years lived with disability (YLDs), years of life lost (YLLs), prevalence, and incidence for all Cancers and 29 cancer groups by sociodemographic index quintile, region and country.

Major cancers are associated with lifestyle, and previous studies have found that the non-immigrant populations in the Nordic countries have higher incidence rates of most cancers than the immigrant populations. However, rates are changing worldwide – so these differences may disappear with time. Here we present recent cancer incidence rates among immigrant and non-immigrant men and women in Norway and investigate whether previous differences still exist. We took advantage of a recent change in the Norwegian Cancer Registry regulations that allow for the registry to have information on country of birth. The number of person years for 2014–2018 was aggregated for every combination of sex, five-year age-group and country of birth, by summing up each year’s population in these groups. The number of cancer cases was then counted for the same groups, and age-standardised incidence rates calculated by weighing the age-specific incidence rates by the Nordic and World standard populations. Further, we calculated incidence rate ratios using the non-immigrant population as a reference. Immigrants from Eastern Europe, the Middle East, Africa and Asia had lower incidence of total cancer compared to the non-immigrant population in Norway and immigrants born in the other Nordic or high-income countries. However, some cancers were more common in certain immigrant groups. Asian men and women had threefold the incidence of liver cancer than non-immigrant men and women. Men from the other Nordic countries and from Eastern Europe had higher lung cancer rates than non-immigrant men. National registries should continuously monitor and present cancer incidence stratified on important population subgroups such as country of birth. This can help assess population subgroup specific needs for cancer prevention and treatment, and could eventually help reduce the morbidity and mortality of cancer.

Lung neoplasms (CIE-9: 162; ICD-10: C33-C34)* resulted in 1.4 % of all deaths. Lung cancer is, among the causes selected in women to be described in this study, which has had the highest annual increase (4.2 %) in the period 1990-2004. In the field of the CAPV there is a pattern of higher mortality in the right bank of the Greater Bilbao region and in Plentzia-Mungia

In 2010, cancer deaths accounted for more than 15% of all deaths worldwide, and this fraction is estimated to rise in the coming years. Increased cancer mortality has been observed in immigrant populations, but a comprehensive analysis by country of birth has not been conducted. We followed all individuals living in Sweden between 1961 and 2009 (7,109,327 men and 6,958,714 women), and calculated crude cancer mortality rates and age-standardized rates (ASRs) using the world population for standardization. We observed a downward trend in all-site ASRs over the past two decades in men regardless of country of birth but no such trend was found in women. All-site cancer mortality increased with decreasing levels of education regardless of sex and country of birth (p for trend <0.001). We also compared cancer mortality rates among foreign-born (13.9%) and Sweden-born (86.1%) individuals and determined the effect of education level and sex estimated by mortality rate ratios (MRRs) using multivariable Poisson regression. All-site cancer mortality was slightly higher among foreign-born than Sweden-born men (MRR = 1.05, 95% confidence interval 1.04–1.07), but similar mortality risks was found among foreign-born and Sweden-born women. Men born in Angola, Laos, and Cambodia had the highest cancer mortality risk. Women born in all countries except Iceland, Denmark, and Mexico had a similar or smaller risk than women born in Sweden. Cancer-specific mortality analysis showed an increased risk for cervical and lung cancer in both sexes but a decreased risk for colon, breast, and prostate cancer mortality among foreign-born compared with Sweden-born individuals. Further studies are required to fully understand the causes of the observed inequalities in mortality across levels of education and countries of birth.